Premium
[P3–205]: EMERGING CSF BIOMARKERS AS PREDICTORS OF ALZHEIMER DISEASE DEMENTIA
Author(s) -
Schindler Suzanne E.,
Herries Elizabeth M.,
Ladenson Jack H.,
Morris John C.,
Fagan Anne M.
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.1418
Subject(s) - neurogranin , cohort , dementia , cerebrospinal fluid , biomarker , medicine , pathological , cognitive decline , alzheimer's disease , snap , disease , tau protein , oncology , psychology , neuroscience , biology , signal transduction , biochemistry , computer graphics (images) , protein kinase c , computer science
APL1b28 peptide in plasma. The concentration of APL1b28 is w0.4pM, which is much less than that in CSF (w500pM). Currently, we are analyzing the APL1b28 ratio in CSF and plasma paired samples. We are also investigating correlation between plasma APL1b28 ratio and CSF Ab42 ratio. Conclusions:We have tried to develop an Ab42 surrogate marker in peripheral blood. We intend to show how and to what degree the plasma APL1b28 ratio correlates with CSF Ab42 ratio.